Natural killer cells and other innate lymphoid cells in cancer
By L. Chiossone, P. Dumas, M. Vienne, É. Vivier. Nature reviews. Immunology, 2018
844 citations recorded by the source corpus.
Subfields: Hematology, Immunology
View Paper: https://www.semanticscholar.org/paper/7ffa5757e016ac6613da73a958573978282d1107
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Immunology
Citations in the corpus
- Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives (2021, background): “NK cell-activating receptors include NK group 2D (NKG2D), NKp30, NKp44, NKp46 and DNAX accessory molecule 1 (DNAM-1), while killer immunoglobulin-like receptors (KIRs) and CD94/NK group 2A (NKG2A) expressed on NK cells are inhibitory receptors [179, 182].”
- Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics (2022, background): “Moreover, T-cell and NK-cell invasion may be facilitated by targeted drugs that modify the tumor endothelium.(239) Gemcitabine, for example, is a deoxycytidine analog that induces tumor cell death, which results in antigen cross-presentation and cross-priming.”
- Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells (2018, background): “Most immunomodulatory strategies to date have focused on enhancing T cell responses, but there has been a recent surge of interest in harnessing the relatively underexplored NK cell compartment for therapeutic interventions (Cerwenka and Lanier, 2018; Guillerey and Smyth, 2016; Rautela et al., 2018;”
- Natural killer cells in cancer biology and therapy (2020, background): “As mentioned above, NK cells are considered a subgroup of ILC1s [6].”
- Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation (2021, background): “HDAC inhibitors have also increased MHC I expression and MHC I pathway components in cancer cell lines (182, 190, 192, 193, 243, 252, 253).”